Activity Overview
This online, on-demand virtual symposium brings together renowned experts in gastrointestinal (GI) oncology. In this educational program, these experts discuss the biology of RAS mutations and the evolving role of RAS-directed therapies in pancreatic and colorectal cancer. Through case-based learning and panel discussions, faculty place emerging efficacy and safety data in the context of real-world treatment decisions.
This educational activity is an archive of the live symposium held on October 2, 2026.
Target Audience
This educational activity is directed toward medical oncologists, surgical oncologists, radiologists, general scientists, young investigators, advanced practice providers, nurses, and pharmacists interested in GI oncology. Other health care professionals interested in treating these malignancies are also invited to participate.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Evaluate efficacy and safety data from clinical trials of RAS-directed therapies in GI cancers
- Incorporate emerging clinical evidence into personalized treatment strategies for patients with GI malignancies
- Apply proactive strategies to monitor and manage treatment-related toxicities associated with RAS-directed therapies in GI cancers

Eileen M. O’Reilly, MD, FASCO
Winthrop Rockefeller Endowed Chair in Medical Oncology
Section Head, Hepatopancreaticobiliary and Neuroendocrine Cancers
Chair, Human Research Protection Program & IRB
Co-Director, Medical, David M. Rubenstein Center for Pancreatic
Cancer Research
Attending Physician, Member
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medicine
New York, NY
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: Uncompensated: Actithera, Agenus, Amgen, Arcus, Astellas, AstraZeneca, BioNTech, Bristol Myers Squibb, Corcept, Ikena, Immuneering, Ipsen, Merck, MOMA Therapeutics, Novartis, Pfizer, Regeneron, Revolution Medicines, Silexion, SystImmune, Tango Therapeutics, Verastem; Grant/Research Funding: Agenus, Amgen, Arcus, AstraZeneca, BioNTech, Digestive Care, Elicio Therapeutics, Genentech/Roche, Incyte, Revolution Medicines, Tango Therapeutics

Tanios S. Bekaii-Saab, MD
David F. and Margaret T. Grohne Professor of Novel Therapeutics
for Cancer Research I
Chair, Division of Hematology and Medical Oncology
Mayo Clinic in Arizona
Phoenix, AZ
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: Consulting (to institution): Arcus, Bayer, Eisai, Genentech, Incyte, Ipsen, Merck KGaA, Merus, Pfizer, Revolution Medicines, Seagen, Servier; Consulting (to self): AbbVie, Arsenal Bio, AstraZeneca, BeiGene, Blueprint Medicines, Boehringer Ingelheim, Caladrius Biosciences, Celularity, Daiichi Sankyo, Deciphera, Exact Sciences, Exelixis, Foundation Medicine, GSK, Illumina, Janssen, Kanaph Therapeutics, Natera, Sanofi, Sobi, Stemline, Takeda, Treos Bio, Xilio Therapeutics and Ryght AI, Zai Lab; Grant/Research Funding: Research Funding (to institution): AbGenomics, Agios Pharmaceuticals, Arcus Biosciences, Arys, Atreca, Bayer, Boston Biomedical, Bristol Myers Squibb, Celgene, Clovis, Eisai, Genentech, Incyte, Ipsen, Lilly, Merus, Mirati, Novartis, Pfizer, Revolution Medicines, Seagen; Royalty or Patent Benefits: Inventions/Patents: WO/2018/183488: HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF – Licensed to Imugene; WO/2019/055687: METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA – Licensed to Recursion Pharmaceuticals; Other: IDMC/DSMB: AstraZeneca, Exelixis, FibroGen, Merck/Eisai; Suzhou Kintor Pharmaceuticals; Scientific Advisory Board: Artiva Biotherapeutics, Immuneering, Imugene, Replimune, Xilis

Bassel F. El-Rayes, MD
Professor
Deputy Director, Moores Cancer Center
University of California San Diego
La Jolla, CA
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: Exelixis, Revolution Medicines, Taiho Oncology; Grant/Research Funding: BeOne Medicines, ProDa BioTech

Wungki Park, MD, MS
Assistant Attending
Assistant Professor
Memorial Sloan Kettering Cancer Center
Weill Cornell Medicine
New York, NY
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: Astellas, IMGT, Innovent Biologics, Regeneron, Revolution Medicines; Grant/Research Funding: Research funding to institution: Amgen, Astellas, Fortvita, Lepu Biopharma, Merck, Revolution Medicines, Verastem Oncology; Travel support: Amgen

John H. Strickler, MD
Senior Associate Consultant
Division of Hematology Oncology
Mayo Clinic
Jacksonville, FL
Disclosures: Advisor, Consultant, Fee-for-Service Recipient: AbbVie, Alterome, Amgen, Astellas, AstraZeneca, Bayer, BeOne Medicines, Boehringer Ingelheim, Bristol Myers Squibb, Cervero, Cytovation, Daiichi Sankyo, Exelixis, Full-Life Technologies, GE Healthcare, Greywolf Therapeutics, GSK, Incyte, Ipsen, Jazz Pharmaceuticals, Johnson & Johnson, Leap, Lilly, Merck, Natera, Pfizer, Pheon Therapeutics, Quanta Therapeutics, Regeneron, Revolution Medicines, Roche/Genentech, Sanofi, Servier, Taiho, Takeda, Tempus, Xilio Therapeutics; Grant/Research Funding: AbbVie, Alterome, Amgen, Apollo Therapeutics, Astellas, Bayer, BeOne Medicines, Daiichi Sankyo, GSK, Leap Therapeutics, Lilly, Novartis, Pfizer, Pheon Therapeutics, Quanta Therapeutics, Regeneron, Revolution Medicines, Roche/Genentech, Servier; Ownership interests in privately held companies: Triumvira Immunologics
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Additional Disclaimers
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
This accredited activity has been developed in accordance with applicable accreditation standards to ensure balance, independence, objectivity, and scientific rigor. Faculty were instructed to use generic names where possible and to base recommendations on the best available evidence.
In the context of clinical discussion, proprietary product names may be mentioned. Such references are made for educational purposes only and do not constitute endorsement of any commercial product or service.
Learners are encouraged to independently evaluate the information presented and apply their own clinical judgment when considering patient care decisions.
Introduction
After the live session, Wungki Park, MD, MSc, sat down on camera to take on the audience questions that time hadn’t allowed. In these segments, Dr Park discusses whether to reduce the dose of pan-RAS inhibitors when starting treatment, what took the most time to learn when using novel KRAS inhibitors, how he approaches resistance to KRAS inhibition in pancreatic ductal adenocarcinoma (PDAC), whether there is a rationale for rechallenge after chemotherapy, which research efforts have his attention, where KRAS inhibitors with different mechanisms of action fit, and which biomarkers are maturing in pancreatic cancer.
Is dose reduction of pan-RAS inhibitors at the time of treatment initiation something you pursue?
What was one aspect of using these novel KRAS inhibitors that took the most time to learn to manage?
What is your current strategy to approach managing resistance to KRAS inhibitors in patients with PDAC?
In a patient who progresses on a KRAS inhibitor and is able to receive chemotherapy, is there any rationale to rechallenge with the KRAS inhibitor upon progression?
What are the research efforts that have the most of your attention for KRAS-mutant PDAC at this time?
Where do KRAS inhibitors with different mechanisms of action fit into the treatment landscape, in your view?
Are there any biomarkers reaching a state of maturity for pancreatic cancer?

GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here